BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26159051)

  • 1. Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.
    Matthes T; Manfroi B; Zeller A; Dunand-Sauthier I; Bogen B; Huard B
    Leukemia; 2015 Sep; 29(9):1882-90. PubMed ID: 26159051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow.
    Matthes T; McKee T; Dunand-Sauthier I; Manfroi B; Park S; Passweg J; Huard B
    Leukemia; 2015 Sep; 29(9):1901-8. PubMed ID: 25753925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow.
    Matthes T; Dunand-Sauthier I; Santiago-Raber ML; Krause KH; Donze O; Passweg J; McKee T; Huard B
    Blood; 2011 Aug; 118(7):1838-44. PubMed ID: 21642598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
    Giuliani N; Colla S; Morandi F; Rizzoli V
    Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
    Tai YT; Acharya C; An G; Moschetta M; Zhong MY; Feng X; Cea M; Cagnetta A; Wen K; van Eenennaam H; van Elsas A; Qiu L; Richardson P; Munshi N; Anderson KC
    Blood; 2016 Jun; 127(25):3225-36. PubMed ID: 27127303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.
    Ramachandran IR; Condamine T; Lin C; Herlihy SE; Garfall A; Vogl DT; Gabrilovich DI; Nefedova Y
    Cancer Lett; 2016 Feb; 371(1):117-24. PubMed ID: 26639197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting IL-6 antagonism in multiple myeloma.
    Matthes T; Manfroi B; Huard B
    Crit Rev Oncol Hematol; 2016 Sep; 105():1-4. PubMed ID: 27497026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
    Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
    Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
    Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
    Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow myeloid cells in regulation of multiple myeloma progression.
    Herlihy SE; Lin C; Nefedova Y
    Cancer Immunol Immunother; 2017 Aug; 66(8):1007-1014. PubMed ID: 28378067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.
    Furukawa M; Ohkawara H; Ogawa K; Ikeda K; Ueda K; Shichishima-Nakamura A; Ito E; Imai JI; Yanagisawa Y; Honma R; Watanabe S; Waguri S; Ikezoe T; Takeishi Y
    J Biol Chem; 2017 Mar; 292(10):4280-4292. PubMed ID: 28154173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
    Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
    Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells.
    Chen L; Wei XQ; Evans B; Jiang W; Aeschlimann D
    Eur J Immunol; 2008 Oct; 38(10):2845-54. PubMed ID: 18958885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
    Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
    J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
    Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
    Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
    Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
    Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
    Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
    Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.
    Klein B; Zhang XG; Jourdan M; Boiron JM; Portier M; Lu ZY; Wijdenes J; Brochier J; Bataille R
    Eur Cytokine Netw; 1990; 1(4):193-201. PubMed ID: 2104241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma.
    Lichtenstein A; Berenson J; Norman D; Chang MP; Carlile A
    Blood; 1989 Sep; 74(4):1266-73. PubMed ID: 2475182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.